EORTC QLQ-C30
nausea/vomiting, dyspnea, fatigue, diarrhea, pain, constipation, insomnia
APPETITE LOSS
QoL at baseline and days 8, 29, 71, 127, and 183 (26 weeks) of C5 inhibitor treatment was measured using the EORTC QLQ-C30 version 3.0. The EORTC QLQ-C30 contains 30 items covering: five function subscales (physical, role, emotional, cognitive, social); nine symptom subscales/items (fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties); and a global health (GH) status/QoL subscale [